DermTech, Inc.

DermTech, Inc. (Nasdaq: DMTK) is a precision dermatology company focused on non-invasive genomic diagnostics for skin cancer detection, operating in the healthcare and molecular diagnostics sector. The company became publicly traded through its business combination with Constellation Alpha Capital Corp., a healthcare-focused SPAC sponsored by Constellation Alpha Capital Group, which completed its IPO in 2017. The February 2019 Form 10-Q filing, bearing accession number 0001144204-19-008105, reflects DermTech's status as a newly combined public company in the quarters following that merger's close. For comprehensive SPAC deal data, sponsor histories, and post-merger filing timelines on DermTech and hundreds of other transactions, sign up for full access at SpacDesk.